| Verified against primary record | |
| Definition | Use of an approved medicine for an unapproved condition, in a different form, or at a different dose[1] |
|---|---|
| Lawfulness of the practice | Lawful: prescribing is governed by medical licensing and practice law rather than by the medicines regulator[2] |
| European Union position | Off-label prescribing is not prohibited or even regulated by Union law; use in medical practice is a national competence[3] |
| Independently reported | |
| Prescriber’s position | A prescriber may carry greater responsibility off-label than within a licence, and must be satisfied the use serves the patient better than a licensed alternative[4] |
| Bands apply only to the rows beneath them. The prescriber row states professional responsibility as a regulator describes it, and is not a statement of civil liability. | |
Off-label treatment is the use of an approved medicine outside the terms of its approval: for a different condition, by a different route, in a different form or at a different dose. It is lawful, common and in some fields unavoidable. It is also not portable across borders, because what crosses a border is not the prescriber’s judgement but the marketing authorisation.
What it is
The American medicines regulator’s patient-facing description covers use for an unapproved condition, in a different form, or at a different dose, states that once a drug is approved health care providers generally may prescribe it for an unapproved use when they judge it medically appropriate, and states that the agency has not determined the drug to be safe and effective for that unapproved use.[1]
The regulatory division that makes this possible is between firms and practice. Current guidance on communications from firms to health care providers about unapproved uses states that providers generally prescribe approved products for unapproved uses when they judge it medically appropriate, and that prescribing is governed by other authorities including state medical licensing and practice requirements and controlled-substances law. The same guidance governs what a firm may share, permitting source publications such as reprints, clinical practice guidelines and reference texts with specified disclosures, and disqualifying communications that are false or misleading, that omit information providers need, that rely on distorted, fraudulent, retracted or scientifically outdated sources, or that use celebrity endorsements, emotional appeals unrelated to scientific content, gifts, tag lines or calls to value that pre-judge benefit for individual patients.[2]
One citation caution belongs here, because the sentence about the regulator governing marketing rather than practice is almost always sourced to a 1998 information sheet. That sheet was withdrawn in April 2024, and two companion sheets on the treatment use of investigational drugs and on charging for investigational products were withdrawn in October 2023; the agency states that withdrawn documents no longer represent its current thinking and are presented for historical purposes.[5] The current guidance above makes the same division in current terms and is the one to rely on.
A national competence in Europe
A paper prepared for a European Commission expert group sets out the position: Union legislation does not regulate the way medicinal products are ultimately used in medical practice, member states hold ultimate responsibility for health policy and the organisation and delivery of health care, off-label use is recognised as a concept in Union pharmaceutical law, and the Court of Justice has held that off-label prescribing is not prohibited, or even regulated, by Union law. The authorised product information sets the approved terms of use; prescribing on or off label is a decision within the relationship between patient and health professional, with prescribers subject to ethical and professional standards and exposed to civil, professional and potentially criminal liability; in countries without specific rules the dominant view is that prescribers handle the issue; and reimbursement depends on national health insurance law, with some national courts limiting it to life-threatening or severe conditions lacking alternatives while two member states explicitly allow it even where alternatives exist.[3]
What the prescriber takes on
A British regulator sets out the prescriber’s responsibilities in plain terms: a prescriber may carry greater responsibility when prescribing off-label than within a licence; off-label prescribing is acceptable where the prescriber judges it in the patient’s best interests on the available evidence, which is common in paediatrics; before prescribing off-label the prescriber must be satisfied the use would serve the patient better than an appropriately licensed alternative, with a sufficient evidence base or experience of safety and efficacy; the prescriber must take responsibility for the prescription and for overseeing care including monitoring and follow-up; the medicine and, where common practice is not followed, the reasons must be recorded; the patient must be given sufficient information including known serious or common adverse reactions to make an informed decision, with an explanation where the evidence is thin or the use is innovative; and suspected adverse reactions must be reported with equal importance to licensed use.[4]
The same regulator’s worked example separates two questions that are frequently merged. Whether a clinician may use a licensed medicine outside its authorisation is one question, and the answer is yes, with additional responsibility and outside the scope of medicines law. Whether someone may place an off-label preparation on the market is a different question, and the answer is no without its own authorisation or an exemption, because medicines law governs placing products on the market; repackaging a concentrate into small aliquots does not by itself make the product unlicensed, but single-dose syringes placed on the market for a different indication, route, dose, presentation and product information would require authorisation.[6]
Why off-label status does not travel
No regulator statement was located addressing off-label use specifically in a cross-border or medical-travel context; the European material frames it as a national-competence question and the American material as a firms-versus-practice question. The position can nonetheless be constructed from what does exist. A member state must accept a prescription issued in another member state for a named patient and allow it to be dispensed under its own rules, but only where the medicine is authorised for marketing in the dispensing state; restrictions on recognition are otherwise prohibited unless necessary, proportionate, non-discriminatory and health-protective, or based on justified doubts about authenticity, content or comprehensibility, and national prescribing, dispensing and substitution rules survive.[7]
What crosses the border, therefore, is the authorisation and not the judgement. A patient prescribed a medicine off-label abroad may find at home that the product is not authorised at all, in which case the prescription is not portable; or that it is authorised but the home clinician declines the off-label use, in which case the patient is asking a second prescriber to assume the responsibility described above for a decision they did not make. Neither outcome is a defect in the foreign prescription.
See also
- Experimental Treatment, the boundary beyond which no authorisation exists to prescribe outside
- Compassionate Use of Medicines, the route for unauthorised products rather than unapproved uses
- Clinical Practice Guidelines, which sometimes recommend uses a licence does not cover
- Cross-Border Healthcare, where prescription recognition is harmonised and referral is not
References
- United States Food and Drug Administration. Understanding unapproved use of approved drugs, "off label". No last-updated date on the fetched content. Verified against primary record: the page was opened and read. Retrieved 10 October 2026.
- United States Food and Drug Administration. Communications from firms to health care providers regarding scientific information on unapproved uses of approved or cleared medical products: questions and answers. Final guidance, January 2025, revision 2. Verified against primary record: the guidance was opened and the division between firm communications and prescribing, and the disqualifying features of a communication, read. The guidance is nonbinding and states that certain of its provisions are not for current implementation pending review. Retrieved 10 October 2026.
- European Commission, Directorate-General for Health and Food Safety. Off-label use of medicinal products. STAMP expert group background paper, meeting of 14 March 2017. Verified against primary record: the paper was opened and the statements on Union competence, the Court of Justice position, prescriber liability and national reimbursement read. Retrieved 10 October 2026.
- Medicines and Healthcare products Regulatory Agency. Off-label or unlicensed use of medicines: prescribers’ responsibilities. Published 11 December 2014, based on a 2009 original. Verified against primary record: the guidance was opened and the prescriber responsibilities, recording and information duties and reporting requirement read. The page addresses professional responsibility rather than civil liability. Retrieved 10 October 2026.
- United States Food and Drug Administration. Withdrawn or expired clinical trial guidance documents. Verified against primary record: the withdrawal list was opened and the withdrawal of the 1998 off-label and investigational use information sheet in April 2024, and of two companion sheets in October 2023, confirmed. Retrieved 10 October 2026.
- Medicines and Healthcare products Regulatory Agency. Review of MHRA published statements on the supply and use of Avastin (bevacizumab) for intravitreal use. 2019. Verified against primary record: the statement was opened and the separation between clinical off-label use and placing a product on the market read. Retrieved 10 October 2026.
- European Parliament and Council. Directive 2011/24/EU, Article 11: recognition of prescriptions issued in another Member State. Adopted 9 March 2011. Verified against primary record: the article text was opened and the recognition rule, its marketing-authorisation condition and the permitted restrictions read. Retrieved 10 October 2026.
Sourcing note: the familiar formulation that the American regulator governs marketing rather than the practice of medicine is usually cited to a 1998 information sheet. That sheet was confirmed withdrawn during this work and is not cited here; the January 2025 guidance is used instead. No regulator statement on off-label use in a cross-border setting was located, and the position set out in the final section is constructed from the prescription-recognition rule and the national-competence finding rather than attributed to any authority.